CN112351997B - 与cd19结合的重链抗体 - Google Patents

与cd19结合的重链抗体 Download PDF

Info

Publication number
CN112351997B
CN112351997B CN201980035712.8A CN201980035712A CN112351997B CN 112351997 B CN112351997 B CN 112351997B CN 201980035712 A CN201980035712 A CN 201980035712A CN 112351997 B CN112351997 B CN 112351997B
Authority
CN
China
Prior art keywords
heavy chain
antibody
antibodies
binding
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980035712.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN112351997A (zh
Inventor
S·F·奥尔德雷德
W·范斯霍滕
K·哈里斯
U·兰加斯瓦米
N·特林克莱因
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tannio Ii
Original Assignee
Tannio Ii
TeneoBio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tannio Ii, TeneoBio Inc filed Critical Tannio Ii
Priority to CN202310539593.8A priority Critical patent/CN116769032A/zh
Publication of CN112351997A publication Critical patent/CN112351997A/zh
Application granted granted Critical
Publication of CN112351997B publication Critical patent/CN112351997B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980035712.8A 2018-07-20 2019-07-19 与cd19结合的重链抗体 Active CN112351997B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310539593.8A CN116769032A (zh) 2018-07-20 2019-07-19 与cd19结合的重链抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701281P 2018-07-20 2018-07-20
US62/701,281 2018-07-20
PCT/US2019/042633 WO2020018922A1 (en) 2018-07-20 2019-07-19 Heavy chain antibodies binding to cd19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310539593.8A Division CN116769032A (zh) 2018-07-20 2019-07-19 与cd19结合的重链抗体

Publications (2)

Publication Number Publication Date
CN112351997A CN112351997A (zh) 2021-02-09
CN112351997B true CN112351997B (zh) 2023-05-26

Family

ID=67515196

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980035712.8A Active CN112351997B (zh) 2018-07-20 2019-07-19 与cd19结合的重链抗体
CN202310539593.8A Pending CN116769032A (zh) 2018-07-20 2019-07-19 与cd19结合的重链抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310539593.8A Pending CN116769032A (zh) 2018-07-20 2019-07-19 与cd19结合的重链抗体

Country Status (21)

Country Link
US (1) US12202898B2 (enExample)
EP (2) EP3823990B1 (enExample)
JP (2) JP7439046B2 (enExample)
KR (2) KR102930803B1 (enExample)
CN (2) CN112351997B (enExample)
AU (1) AU2019305663B2 (enExample)
BR (1) BR112020024074A2 (enExample)
CA (1) CA3101069A1 (enExample)
DK (1) DK3823990T3 (enExample)
ES (1) ES3064933T3 (enExample)
FI (1) FI3823990T3 (enExample)
HR (1) HRP20260372T1 (enExample)
IL (2) IL326259A (enExample)
LT (1) LT3823990T (enExample)
MX (1) MX2021000708A (enExample)
PL (1) PL3823990T3 (enExample)
PT (1) PT3823990T (enExample)
RS (1) RS67881B1 (enExample)
SG (1) SG11202011597RA (enExample)
SM (1) SMT202600121T1 (enExample)
WO (1) WO2020018922A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109641049B (zh) 2016-06-21 2023-07-07 特尼奥生物股份有限公司 Cd3结合抗体
RU2762835C2 (ru) 2016-08-24 2021-12-23 Тенеобио, Инк. Трансгенные животные, отличные от человека, продуцирующие модифицированные антитела, содержащие только тяжелые цепи
MY200988A (en) 2016-09-14 2024-01-27 Teneobio Inc CD3 Binding Antibodies
KR102745676B1 (ko) 2016-12-21 2024-12-24 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
WO2018237006A1 (en) 2017-06-20 2018-12-27 Teneoone, Inc. Anti-bcma heavy chain-only antibodies
IL312322B2 (en) 2017-06-20 2026-05-01 Teneobio Inc Antibodies against BCMA containing only heavy chains
WO2019126756A1 (en) 2017-12-22 2019-06-27 Teneobio, Inc. Heavy chain antibodies binding to cd22
BR112020024074A2 (pt) 2018-07-20 2021-02-17 Teneobio, Inc. anticorpos de cadeia pesada com ligação a cd19
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
CR20210500A (es) 2019-04-05 2021-11-05 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
JP7665538B2 (ja) 2019-06-14 2025-04-21 テネオバイオ， インコーポレイテッド Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
EP4592310A2 (en) * 2020-03-16 2025-07-30 Angeles Therapeutics, Inc. Novel antigen binding domains and synthetic antigen receptors incorporating the same
WO2021222578A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
IL297601A (en) 2020-04-29 2022-12-01 Teneobio Inc Multispecific heavy chain antibodies with modified heavy chain constant regions
EP4182351A4 (en) * 2020-07-16 2024-12-11 Legend Biotech Ireland Limited CD19-BINDING MOLECULES AND THEIR USES
WO2022012680A1 (en) 2020-07-16 2022-01-20 Nanjing Legend Biotech Co., Ltd. Cd20 binding molecules and uses thereof
WO2022060901A1 (en) 2020-09-16 2022-03-24 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
KR20230166090A (ko) * 2021-04-06 2023-12-06 테네오바이오, 인코포레이티드 항-cd19 항체 및 car-t 구조체
WO2024243093A2 (en) * 2023-05-19 2024-11-28 The Regents Of The University Of California Multispecific antibodies targeting cd3 and cd22
EP4566619A1 (en) 2023-12-08 2025-06-11 AvenCell Therapeutics Inc. Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal
WO2025222102A1 (en) * 2024-04-19 2025-10-23 TeneoTwo, Inc. Therapeutic combinations of acalabrutinib and a multispecific antibody to treat b-cell malignancies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006089133A2 (en) * 2005-02-15 2006-08-24 Duke University Anti-cd19 antibodies and uses in oncology
CN101218351A (zh) * 2005-02-15 2008-07-09 杜克大学 抗cd19抗体及其在肿瘤学中的应用
CN102119174A (zh) * 2008-07-17 2011-07-06 诺瓦提斯公司 使用治疗性抗体的组合物和方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US6066721A (en) 1995-07-06 2000-05-23 Stanford University Method to produce novel polyketides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
ATE279947T1 (de) 1996-03-18 2004-11-15 Univ Texas Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
AU6232899A (en) 1999-10-06 2001-05-10 Campina Melkunie B.V. Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2438682A1 (en) 2001-02-20 2002-08-29 Zymogenetics, Inc. Antibodies that bind both bcma and taci
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP1578447A4 (en) 2002-10-31 2009-06-03 Genentech Inc METHOD AND COMPOSITIONS FOR INCREASING ANTIBODY PRODUCTION
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
US20060008548A1 (en) 2003-11-19 2006-01-12 Invista North America S.A R.L. Spinneret plate for producing a bulked continuous filament having a three-sided exterior cross-section and a convex six-sided central void
EP1978032A3 (en) 2004-07-22 2009-02-18 Erasmus University Medical Center Rotterdam Binding molecules
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
CA2688834C (en) 2007-06-01 2020-01-07 Ronald Buelow Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
KR101589785B1 (ko) 2009-03-10 2016-01-28 바이오젠 엠에이 인코포레이티드 항-ｂｃｍａ 항체
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US9963513B2 (en) 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
AP2017009823A0 (en) * 2014-09-26 2017-03-31 Macrogenics Inc Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
US9914683B2 (en) * 2016-05-26 2018-03-13 X Development Llc Fuel synthesis from an aqueous solution
CN109641049B (zh) 2016-06-21 2023-07-07 特尼奥生物股份有限公司 Cd3结合抗体
RU2762835C2 (ru) 2016-08-24 2021-12-23 Тенеобио, Инк. Трансгенные животные, отличные от человека, продуцирующие модифицированные антитела, содержащие только тяжелые цепи
MY200988A (en) 2016-09-14 2024-01-27 Teneobio Inc CD3 Binding Antibodies
KR102745676B1 (ko) 2016-12-21 2024-12-24 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
WO2018237006A1 (en) 2017-06-20 2018-12-27 Teneoone, Inc. Anti-bcma heavy chain-only antibodies
IL312322B2 (en) 2017-06-20 2026-05-01 Teneobio Inc Antibodies against BCMA containing only heavy chains
KR102757010B1 (ko) 2017-06-30 2025-01-23 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 인간 도메인을 갖는 항-b 세포 성숙화 항원 키메라성 항원 수용체
BR112020013086A2 (pt) 2017-12-27 2020-12-08 Teneobio, Inc. Anticorpos específicos de heterodímero de cd3-delta/épsilon
CA3101340A1 (en) 2018-05-24 2019-11-28 Ayala Pharmaceuticals Inc. Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof
BR112020024074A2 (pt) 2018-07-20 2021-02-17 Teneobio, Inc. anticorpos de cadeia pesada com ligação a cd19
JP7665538B2 (ja) 2019-06-14 2025-04-21 テネオバイオ， インコーポレイテッド Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
IL297601A (en) 2020-04-29 2022-12-01 Teneobio Inc Multispecific heavy chain antibodies with modified heavy chain constant regions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006089133A2 (en) * 2005-02-15 2006-08-24 Duke University Anti-cd19 antibodies and uses in oncology
CN101218351A (zh) * 2005-02-15 2008-07-09 杜克大学 抗cd19抗体及其在肿瘤学中的应用
CN102119174A (zh) * 2008-07-17 2011-07-06 诺瓦提斯公司 使用治疗性抗体的组合物和方法

Also Published As

Publication number Publication date
RS67881B1 (sr) 2026-04-30
IL279010B1 (en) 2026-03-01
JP7737488B2 (ja) 2025-09-10
JP2024073430A (ja) 2024-05-29
LT3823990T (lt) 2026-04-10
US20210332133A1 (en) 2021-10-28
EP4714502A2 (en) 2026-03-25
MX2021000708A (es) 2021-03-25
KR20260036383A (ko) 2026-03-16
BR112020024074A2 (pt) 2021-02-17
SG11202011597RA (en) 2020-12-30
PL3823990T3 (pl) 2026-04-20
CN116769032A (zh) 2023-09-19
EP3823990B1 (en) 2025-12-17
IL326259A (en) 2026-03-01
DK3823990T3 (da) 2026-03-16
KR102930803B1 (ko) 2026-02-26
PT3823990T (pt) 2026-03-20
JP2021530236A (ja) 2021-11-11
AU2019305663B2 (en) 2026-04-02
SMT202600121T1 (it) 2026-05-12
IL279010A (en) 2021-01-31
KR20210032311A (ko) 2021-03-24
HRP20260372T1 (hr) 2026-04-24
EP3823990A1 (en) 2021-05-26
CA3101069A1 (en) 2020-01-23
AU2019305663A1 (en) 2021-03-11
FI3823990T3 (fi) 2026-03-16
US12202898B2 (en) 2025-01-21
WO2020018922A1 (en) 2020-01-23
ES3064933T3 (en) 2026-04-30
JP7439046B2 (ja) 2024-02-27
CN112351997A (zh) 2021-02-09

Similar Documents

Publication Publication Date Title
JP7737488B2 (ja) Ｃｄ１９に結合する重鎖抗体
US12180298B2 (en) Heavy chain antibodies binding to PSMA
JP7665538B2 (ja) Ｃｄ２２及びｃｄ３に結合する多重特異性重鎖抗体
KR20230148828A (ko) 항-psma 항체 및 car-t 구조
WO2022221698A1 (en) Anti-cd20 antibodies and car-t structures
CA3199785A1 (en) Heavy chain antibodies binding to folate receptor alpha
RU2824170C2 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с cd19
HK40100966A (zh) 与cd19结合的重链抗体
EA048216B1 (ru) Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3
CN117120472A (zh) 抗cd19抗体及car-t结构
HK40044275B (en) Heavy chain antibodies binding to cd19
HK40044275A (en) Heavy chain antibodies binding to cd19
HK40036534B (en) Heavy chain antibodies binding to cd22

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230323

Address after: California, USA

Applicant after: Tannio II

Address before: California, USA

Applicant before: TeneoBio, Inc.

GR01 Patent grant
GR01 Patent grant